2018

5-years relapse-free survival and predictive factors identification in HR-positive HER2-negative breast cancer patients treated with anastrozole or fulvestrant neoadjuvant endocrine therapy: Pooled analysis of the CARMINA02 and HORGEN phase II trials

Congress : EBCC

Authors : F Lerebours, M Pulido, E Fourme, M Debled, V. Becette, H. Bonnefoi, S. Rivera, G. Mac Grogan, MA Mouret-Reynier,  C. Tunon de Lara, JY Pierga, C Breton Callu, L Venat-Bouvet, S Mathoulin-Pélissier, P Kerbrat, F Dalenc, B. Sigal, T Bachelot, J Lemonnier, N Quenel-Tueux.

Experts group or program : French Breast Cancer Intergroup (UCBG)

En savoir plus